Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros

Banco de datos
Tipo de estudio
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Mol Psychiatry ; 27(11): 4419-4431, 2022 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-35974141

RESUMEN

Understanding the genomic basis of memory processes may help in combating neurodegenerative disorders. Hence, we examined the associations of common genetic variants with verbal short-term memory and verbal learning in adults without dementia or stroke (N = 53,637). We identified novel loci in the intronic region of CDH18, and at 13q21 and 3p21.1, as well as an expected signal in the APOE/APOC1/TOMM40 region. These results replicated in an independent sample. Functional and bioinformatic analyses supported many of these loci and further implicated POC1. We showed that polygenic score for verbal learning associated with brain activation in right parieto-occipital region during working memory task. Finally, we showed genetic correlations of these memory traits with several neurocognitive and health outcomes. Our findings suggest a role of several genomic loci in verbal memory processes.


Asunto(s)
Aprendizaje , Memoria a Corto Plazo , Memoria a Corto Plazo/fisiología , Aprendizaje Verbal , Herencia Multifactorial , Encéfalo
2.
Int J Cancer ; 141(7): 1458-1468, 2017 10 01.
Artículo en Inglés | MEDLINE | ID: mdl-28614908

RESUMEN

Systemic high dose interleukin-2 (IL-2) postconditioning has long been utilized in boosting the efficacy of T cells in adoptive cell therapy (ACT) of solid tumors. The resulting severe off-target toxicity of these regimens renders local production at the tumor an attractive concept with possible safety gains. We evaluated the efficacy and safety of intratumorally administered IL-2-coding adenoviruses in combination with tumor-infiltrating lymphocyte therapy in syngeneic Syrian hamsters bearing HapT1 pancreatic tumors and with T cell receptor transgenic ACT in B16.OVA melanoma bearing C57BL/6 mice. The models are complementary: hamsters are semi-permissive for human oncolytic adenovirus, whereas detailed immunological analyses are possible in mice. In both models, local production of IL-2 successfully replaced the need for systemic recombinant IL-2 (rIL-2) administration and increased the efficacy of the cell therapy. Furthermore, vectored delivery of IL-2 significantly enhanced the infiltration of CD8+ T cells, M1-like macrophages, and B-cells while systemic rIL-2 increased CD25 + FoxP3+ T cells at the tumor. In contrast with vectored delivery, histopathological analysis of systemic rIL-2-treated animals revealed significant changes in lungs, livers, hearts, spleens, and kidneys. In summary, local IL-2 production results in efficacy and safety gains in the context of ACT. These preclinical assessments provide the rationale for ongoing clinical translation.


Asunto(s)
Adenoviridae/metabolismo , Inmunoterapia Adoptiva/métodos , Interleucina-2/biosíntesis , Linfocitos Infiltrantes de Tumor/inmunología , Melanoma Experimental/terapia , Neoplasias Pancreáticas/terapia , Adenoviridae/inmunología , Traslado Adoptivo/métodos , Animales , Linfocitos B/inmunología , Linfocitos T CD8-positivos/inmunología , Movimiento Celular/inmunología , Cricetinae , Modelos Animales de Enfermedad , Femenino , Factores de Transcripción Forkhead/inmunología , Vectores Genéticos , Mediadores de Inflamación/sangre , Interleucina-2/administración & dosificación , Interleucina-2/inmunología , Subunidad alfa del Receptor de Interleucina-2/inmunología , Pulmón/irrigación sanguínea , Pulmón/patología , Linfocitos Infiltrantes de Tumor/trasplante , Macrófagos/inmunología , Masculino , Melanoma Experimental/inmunología , Mesocricetus , Ratones , Ratones Endogámicos C57BL , Neoplasias Pancreáticas/inmunología , Distribución Aleatoria , Proteínas Recombinantes/administración & dosificación , Proteínas Recombinantes/inmunología
3.
Mol Ther Oncolytics ; 4: 77-86, 2017 Mar 17.
Artículo en Inglés | MEDLINE | ID: mdl-28345026

RESUMEN

Adoptive cell therapy holds much promise in the treatment of cancer but results in solid tumors have been modest. The notable exception is tumor-infiltrating lymphocyte (TIL) therapy of melanoma, but this approach only works with high-dose preconditioning chemotherapy and systemic interleukin (IL)-2 postconditioning, both of which are associated with toxicities. To improve and broaden the applicability of adoptive cell transfer, we constructed oncolytic adenoviruses coding for human IL-2 (hIL2), tumor necrosis factor alpha (TNF-α), or both. The viruses showed potent antitumor efficacy against human tumors in immunocompromised severe combined immunodeficiency (SCID) mice. In immunocompetent Syrian hamsters, we combined the viruses with TIL transfer and were able to cure 100% of the animals. Cured animals were protected against tumor re-challenge, indicating a memory response. Arming with IL-2 and TNF-α increased the frequency of both CD4+ and CD8+ TILs in vivo and augmented splenocyte proliferation ex vivo, suggesting that the cytokines were important for T cell persistence and proliferation. Cytokine expression was limited to tumors and treatment-related signs of systemic toxicity were absent, suggesting safety. To conclude, cytokine-armed oncolytic adenoviruses enhanced adoptive cell therapy by favorable alteration of the tumor microenvironment. A clinical trial is in progress to study the utility of Ad5/3-E2F-d24-hTNFa-IRES-hIL2 (TILT-123) in human patients with cancer.

SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA